The business’s quarterly earnings decreased from $6.85 billion to $6.84 billion. Refinitiv reports that the amount exceeded analyst projections of $6.77 billion.
In 2020, Amgen and Eli Lilly agreed to increase Eli Lilly’s supply of medications based on antibodies. As a result of their conclusion that the COVID-19 antibodies from Eli Lilly were ineffective against currently widespread variations, U.S. health regulators revoked their authorisation for them in November.
Additionally, the biotech firm reported a decrease in “revenue from other sources,” which includes the manufacturing arrangement, from $575 million to $287 million.
The osteoporosis medicine Prolia, whose sales increased 14% to a quarterly record of $992 million, led all Amgen products in terms of sales.
source: cnn.com
